Clinical Trials

Phase 2 Active not recruiting

Melanoma

NCT02743819 2025-06-10

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

70 enrolled 11 charts

Melanoma

NCT02437136 2025-03-20

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Phase 1/2 Completed

191 enrolled 26 charts

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04032704 2025-03-10

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

205 enrolled 54 charts

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT03747484 2025-03-06

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Phase 1/2 Terminated

7 enrolled 15 charts

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT03665597 2025-02-10

KEYNOTE-555

138 enrolled 34 charts 2 FDA

Melanoma

NCT02500576 2025-01-15

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

18 enrolled 13 charts

Melanoma

NCT04068181 2025-01-07

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

72 enrolled 28 charts

Melanoma

NCT03092453 2024-12-24

Dendritic Cell Vaccination in Patients With Advanced Melanoma

5 enrolled 10 charts

Phase 3 Active not recruiting

Melanoma

NCT03553836 2024-11-29

KEYNOTE-716

976 enrolled 15 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02791594 2024-11-08

Imaging FDG Flare in Melanoma

Completed

21 enrolled 10 charts

Melanoma

NCT03341143 2024-10-30

Fecal Microbiota Transplant (FMT) in Melanoma Patients

20 enrolled 19 charts

Melanoma

NCT03476174 2024-10-02

Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma

1 enrolled 9 charts

Melanoma

NCT03200847 2024-10-01

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Phase 1/2 Completed

26 enrolled 13 charts

Melanoma

NCT04768881 2024-08-23

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

15 enrolled 15 charts

Melanoma

NCT03620019 2024-08-12

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

25 enrolled 16 charts

Melanoma

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

DermatologicGastrointestinalLymphoidSarcomaThoracic

58 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT04152863 2024-08-06

V937-011

85 enrolled 19 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03621982 2024-06-13

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Phase 1 Terminated

78 enrolled 39 charts

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT02821000 2024-05-30

Keynote-151

103 enrolled 30 charts

Melanoma

NCT04148937 2024-04-05

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

52 enrolled 21 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT03765229 2024-01-10

An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

11 enrolled 12 charts

Melanoma

NCT03229278 2023-12-06

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

DermatologicGenitourinaryHead & NeckLymphoidThoracic

14 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Melanoma, Neoplasm Metastasis

NCT03089606 2023-11-15

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

27 enrolled 14 charts